Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating results on Tuesday, February 4, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
紐約塔裏鎮，2025年1月7日（環球新聞通訊社）-- 再生元製藥公司（納斯達克：REGN）今天宣佈，將於2025年2月4日星期二美國金融市場開盤前發佈其2024年第四季度和全年財務及運營結果。公司將在當天東部時間上午8:30舉行電話會議和同步網絡廣播。
Conference Call Information
Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at . To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days.
電話會議信息
參與者可以通過再生元公司網站的「投資者和媒體」頁面上的網絡廣播實時訪問電話會議，地址爲 。如果要通過電話參與，請提前在此處註冊 鏈接。註冊後，所有電話參與者將收到一封確認電子郵件，詳細說明如何加入電話會議，包括撥入號碼以及可以用來訪問會議的唯一密碼和註冊者ID。電話會議和網絡廣播的重播及文字記錄將在公司網站上保存至少30天。
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
關於再生元
再生元製藥公司（納斯達克：REGN）是一家領先的生物技術公司，致力於爲患有嚴重疾病的人們發明、開發和商業化改變生命的藥物。由醫師科學家創立並領導，我們獨特的能力使得科學不斷轉化爲醫學，這導致了許多獲得批准的治療方案和在開發中的產品候選者，其中大部分是在我們的實驗室內部創造的。我們的藥物和研發管道旨在幫助患有眼病、過敏和炎症疾病、癌症、心血管和代謝疾病、神經疾病、血液病、傳染病和罕見疾病的患者。
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
再生元不斷推動科學發現的邊界，加速藥物開發，使用我們的專有技術，如VelociSuite，該技術可生成優化的完全人源抗體和新類型的雙特異性抗體。我們正在藉助來自再生元基因中心的數據驅動洞察和開創性的基因醫學平台塑造醫學的下一個前沿，使我們能夠識別創新目標和互補方法，以潛在地治療或治癒疾病。
For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X.
欲獲取更多信息，請訪問。 或關注再生元製藥公司的動態 LinkedIn, Instagram, 臉書 或 X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
| 聯繫信息： | |
| 投資者關係 | 企業通訊 |
| 瑞安·克勞 | 克里斯蒂娜·陳 |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
譯文內容由第三人軟體翻譯。